Incyte

Incyte is a global biopharmaceutical company focused on the discovery, development, and commercialization of proprietary therapeutics. The company is a leader in the field of JAK inhibition and has built a robust portfolio in Oncology, Hematology, and Inflammation & Autoimmunity (IAI). Incyte is best known for its flagship product, Jakafi (ruxolitinib), which was the first FDA-approved JAK inhibitor. Headquartered in Wilmington, Delaware, with significant operations in Switzerland and Japan, Incyte maintains a high-science culture with a heavy reinvestment in R&D. Their strategy involves both internal discovery and strategic acquisitions to expand their pipeline in dermatology and rare diseases, recently highlighted by the commercial success of Opzelura (ruxolitinib cream).